ReviewDrugs2015
Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians).JAC-antimicrobial resistance · 2026Article
- Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting.Infection · 2025Article
- New Antibiotics forAntibiotics (Basel, Switzerland) · 2023Review
- Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].Der Anaesthesist · 2019Article
- Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes ofAntimicrobial agents and chemotherapy · 2019Article
- Attitudes of physicians from 10 European countries on adherence and how treatment modalities in ABSSSI affect adherence: results from a Delphi survey.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.Drugs in context · 2018Article
- Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller : Proposal for novel treatment indications.Wiener klinische Wochenschrift · 2017Article
- Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Drugs · 2017Review
- New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.Therapeutics and clinical risk management · 2016Review
- Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Drugs · 2015Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous dalbavancin (Dalvance™; Xydalba™) is approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI), with the recommended regimen being a 1000 mg dose followed 1 week later by a 500 mg dose. In the multinational DISCOVER 1 and 2 trials in adult patients with ABSSSI, dalbavancin treatment was noninferior to vancomycin (for ≥ 3 days with an option to switch to oral linezolid to complete a 10- to 14-day course) in terms of early clinical success rates (assessed 48-72 h after initiation of treatment; primary endpoint required by the FDA to assess noninferiority in registration trials of ABSSSI). Clinical response rates were also similar in both treatment groups at the end of treatment (day 14-15), irrespective of geographic region or baseline characteristics, including by infection type, diabetes mellitus status, systemic inflammatory response syndrome status, causative pathogen and renal function. Dalbavancin was generally well tolerated, with adverse events generally being of mild to moderate intensity and transient. With its broad spectrum of activity against clinically relevant Gram-positive pathogens and its favourable pharmacokinetic profile that permits a convenient two-dose, once-weekly regimen with no requirement for therapeutic drug monitoring, dalbavancin is a promising emerging option for the treatment of ABSSSI in adult patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.